TLSA: 1H:21 Financial Update
By John Vandermosten, CFANASDAQ:TLSAREAD THE FULL TLSA RESEARCH REPORTFirst Half 2021 ResultsTiziana Life Sciences (NASDAQ:TLSA) updated on first half 2021 financial and operational results in a pres
天演药业公布2021年上半年财务业绩及公司进展
- 与默沙东达成三项临床合作,以推进三个临床抗肿瘤候选产品与帕博利珠单抗的全球联合试验 - - ADG106单药临床试验显示疗效且安全性良好;着力推进生物标志物高表达的适应症及靶向PD-1耐药患者的联合治疗- - 正在进行的 I 期试验显示出全新的抗 CTLA-4新表位抗体(NEObodyTM)ADG116具有高度差异化的临床产品表征 - -首个安全性抗体项目ADG126 I 期临床剂量爬坡顺利
水曜日のアフターマーケットセッションで動いている12のヘルスケア株
水曜日のアフターマーケットセッション中、AIkido Pharma(NASDAQ:AIKI)の株価は8.13%上昇して、0.93ドルとなりました。クローズ時には、AIkido Pharmaの取引量は150万株に達しました。これは、その株式の79.05%に当たります。
PDL BioPharma shares are trading higher after Silver Point Capital disclosed the purchase of 1.565 million shares.
PDL BioPharma shares are trading higher after Silver Point Capital disclosed the purchase of 1.565 million shares.
PDL Biopharma 10%+ Owner Edward Mule Reported Purchase of 1,565,000 Shares @ Avg Price of $2.60/Share in Form 4 Filing on Wednesday
PDL Biopharma 10%+ Owner Edward Mule Reported Purchase of 1,565,000 Shares @ Avg Price of $2.60/Share in Form 4 Filing on Wednesday
Vaxcyte Promotes Andrew Guggenhime to President and Chief Financial Officer
The MarketWatch News Department was not involved in the creation of this content.FOSTER CITY, Calif., Dec 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- FOSTER CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) --
PDL Biopharma 10%+ Owner Edward Mule Reported Purchase of 2,090,000 Shares @ Avg Price of $2.57/Share in Form 4 Filing on Tuesday
PDL Biopharma 10%+ Owner Edward Mule Reported Purchase of 2,090,000 Shares @ Avg Price of $2.57/Share in Form 4 Filing on Tuesday
Is PDLI A Good Stock To Buy Now?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in
PDL BioPharma Enters $51.4M Capital Provision Agreement With Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement With Wellstat
RENO, Nev., Dec. 14, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments
12 Healthcare Stocks Moving In Wednesday's After-Market Session
Gainers Panbela Therapeutics (NASDAQ:PBLA) shares moved upwards by 145.5% to $10.52 during Wednesday's after-market session. Trading volume for this security closed at 244.6K, accounting for 598.65%
PDL BioPharma indicates timeline for Nasdaq voluntarily delisting
PDL BioPharma (NASDAQ:PDLI) -3.9% PM, formally notified The Nasdaq of its intent to delist its common stock from the Nasdaq on or about Dec.28, 2020 and suspend trading prior to the Dec.31 market open
BRIEF-Pdl Announces Timeline For Voluntarily Delisting From Nasdaq
PDL BioPharma Inc PDLI.O :* PDL ANNOUNCES TIMELINE FOR VOLUNTARILY DELISTING FROM NASDAQ* PDL BIOPHARMA INC - TRADING IN PDL&aposS COMMON STOCK ON NASDAQ TO BE SUSPENDED PRIOR TO MARKET OPENING ON
PDL Announces Timeline for Voluntarily Delisting from Nasdaq; Sets Date For Dec. 31, 2020
PDL Announces Timeline for Voluntarily Delisting from Nasdaq INCLINE VILLAGE, Nev., Dec. 8, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) today announced that it has
PDL Announces That It Volybtarily Be Delisting From The Nasdaq On Or About December 28, 2020
PDL Announces That It Volybtarily Be Delisting From The Nasdaq On Or About December 28, 2020
PDL BioPharma Liquidation May Offer 40% Upside For Patient Investors Comfortable With Illiquidity
SummaryPDLI is liquidating, it should delist from the NASDAQ on December 31, 2020.Patient investors can ultimately expect a return of approximately 40% based on net assets.The Glumetza royalties may be undervalued today based on arguably a punitive discount rate, creating closer to 60% upside under a 5% discount rate for the portfolio.There is downside risk too, from payments being pushed out years into the future, a class action related to Glumetza pricing and other uncertainties.On balance, PDLI presents an opportunity for patient investors capable of owning illiquid investments.
Recap: PDL BioPharma Q3 Earnings
Shares of PDL BioPharma (NASDAQ:PDLI) rose 7.96% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 211.11% year over year to ($0.10), whic
PDL BioPharma Q3 EPS $0.04 Misses $0.06 Estimate, Sales $4.12M Miss $5.50M Estimate
PDL BioPharma (NASDAQ:PDLI) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33.33 percent. This is a 55.56 percent decrease over earnings of $0.0
PDL BioPharma 3Q Rev $4.12M >PDLI
*DJ PDL BioPharma 3Q EPS 4c >PDLI (MORE TO FOLLOW) Dow Jones Newswires November 11, 2020 16:05 ET (21:05 GMT) *DJ PDL BioPharma 3Q Rev $4.12M >PDLI (MORE TO FOLLOW) Dow Jones Newswir
Press Release: PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
*DJ PDL BioPharma 3Q EPS 4c >PDLI (MORE TO FOLLOW) Dow Jones Newswires November 11, 2020 16:05 ET (21:05 GMT) *DJ PDL BioPharma 3Q Rev $4.12M >PDLI (MORE TO FOLLOW) Dow Jones Newswir
2020年11月9日に予定されている収益
ベル前に報告する企業 • ゼネラルファイナンス(NASDAQ:GFN)は、株式当たり0.03ドルの四半期利益と、7,742万ドルの収益を報告する見込みです。 • ストラタスプロパティーズ(NASDAQ:STRS)は
データなし